Visible Patient™ With Intravascular Indocyanine Green
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03953144|
Recruitment Status : Not yet recruiting
First Posted : May 16, 2019
Last Update Posted : May 16, 2019
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer Primary Neoplasm||Device: VisiblePatient™ 3D Lung Modelling Drug: IC-Green (ICG)||Phase 1 Phase 2|
Lungs are made up of individual lobes. When a lung cancer tumour is found in one of these lobes, the surgeon often performs a Lobectomy. A Lobectomy is the surgery most commonly done to treat early-stage lung cancer and requires removal of an entire lobe of the lung, which removes a large amount of lung tissue
For patients with small tumours saving as much healthy lung tissue as possible is important. Each lobe of the lung has smaller sections called segments. When a lung cancer is in one of these segments, it is possible to remove that segment, without removing the entire lobe. This surgery is called a Segmentectomy. Compared to a lobectomy, a segmentectomy saves a larger amount of healthy lung tissue. Research shows that a segmentectomy can result in less blood loss, shorter operation time, less days of having a chest tube, and a shorter hospital stay, compared to a lobectomy.
With the advances in screening technology for lung cancer tumours, an increasing amount of very small lung cancer tumours are being found, and the demand for segmentectomy is increasing. A segmentectomy is a hard surgery to perform robotically because it is difficult to view the tissue lines that separate each segment within the lobe. As a result, it is difficult for the surgeon to see exactly which pieces of tissue should be removed in order to safely complete the segmentectomy. Because of these challenges, many patients having robotic surgery will have a lobectomy, even if a full lobectomy is not needed.
In response to these challenges, our surgical group has developed the technique of using Near-Infrared Fluorescence (NIF) mapping with intravascular indocyanine green (ICG) dye injection. With the aid of an infrared camera the surgeon is able to see the segment within a lobe of lung after injection of the ICG dye, allowing for a more accurate segmentectomy. We recently reported a 60% success rate of segmental resections with the use of ICG and NIF-guided surgical resection. However, a limitation to this technique is that the segmental anatomy can only be seen during the operation and only after cutting the blood vessels.
The introduction of 3D reconstruction and virtual modeling provides a new way to locate lesions accurately within a segment and plan the appropriate operation before the actual surgery occurs. Visible Patient™ (Strasbourg, France) is a 3D modelling technology that is capable of producing a detailed 3D virtual model of a patient's lung based on Computed Tomography (CT) scans. It has been shown to be safe and feasible in performing segmental pulmonary resections on a robotic platform. In this study, we propose a new operation that uses 3D anatomical planning before the surgery (Visible Patient™) and real-time NIF-mapping at the time of surgery using ICG dye, which we believe will greatly increase the likelihood of a successful segmentectomy. If this new operation is successful, it will help patients save more of their healthy lung tissue when they are undergoing surgery for lung cancer.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This study is a single centre, prospective clinical trial evaluating the safety and feasibility of adding 3D anatomical reconstructions and real-time intraoperative planning using Visible Patient™ software added to NIF-guided targeted segmental resection. It is anticipated that 32 participants will be enrolled within a 1-year period. Enrollment will take place at St. Joseph's Healthcare Hamilton. All patients enrolled will be evaluated until their first scheduled follow-up appointment (within 30 days post-surgery).|
|Masking:||None (Open Label)|
|Masking Description:||Open Label, single-arm feasibility trial.|
|Official Title:||VISible Patient™ With Intravascular indOcyaNine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection (VISION) Trial: A Phase I Safety and Feasibility Trial|
|Estimated Study Start Date :||August 1, 2019|
|Estimated Primary Completion Date :||August 1, 2020|
|Estimated Study Completion Date :||August 1, 2021|
Experimental: VisiblePatient™ 3D Lung Modelling + IC-GREEN Segmentectomy
Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Visible Patient™ to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
Device: VisiblePatient™ 3D Lung Modelling
The 3D virtual models provided by Visible Patient™ will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
Drug: IC-Green (ICG)
ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Other Name: Indocyanine Green
- Segmental Resection Conversion Rate [ Time Frame: 1 year ]Rate of conversions to lobectomy will be measured by collecting the proportion of conversions to lobectomy.
- Number of Participants with Post Operative Complications [ Time Frame: 1 year ]Post operative complications will be reported and measured using the Ottawa Thoracic Morbidity and Mortality Classification of (a) Adverse reactions to ICG dye at the time of surgery and (b) Perioperative complications through study completion.
- Anatomical Accuracy of the 3D Lung Model [ Time Frame: 1 year ]
Anatomical accuracy will be evaluated using the criteria listed in points a-c. A score of 3/3 on these items will indicate success of anatomical accuracy
- Ex-vivo localization of lesions;
- Ex-vivo confirmation of tumor-free margins around lesion;
- Ex-vivo confirmation of adequate anatomical inter-segmental.
- Surgeon Confidence [ Time Frame: 1 year ]
A pre-operative CT scan based, a pre-operative 3D reconstruction based and post segmental resection surgeon confidence score will be obtained on a scale of 1-5:
1 - not at all confident, 2 - somewhat confident, 3 - confident, 4 - very confident, 5 - extremely confident.
- Operation Time [ Time Frame: 1 year ]Length of time of the operation will be measured by collecting the time the patient entered the operating room until the time the patient left the operating room.
- Conversion to Thoracotomy [ Time Frame: 1 year ]Rate of conversion to thoracotomy will be measured by collecting the proportion of conversions to thoracotomy. Descriptive analysis of reasons for conversion will also be collected.
- Chest Tube Duration [ Time Frame: 1 year ]Duration the patient had chest tubes in situ will be measured by collecting the date of surgery and the date the chest tube was removed.
- Length of Stay [ Time Frame: 1 year ]Duration of hospital length of stay will be measured by collecting the data of admission and the date of discharge.
- Estimated Blood Loss [ Time Frame: 1 year ]Estimated blood loss will be measured at the time of operation by OR staff.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03953144
|Contact: Peter R. A. Malik, BHSc (Honours)||905-522-1155 ext firstname.lastname@example.org|
|Contact: Yogita S Patel, BSc||905-522-1155 ext email@example.com|
|St. Josephs Healthcare Hamilton||Not yet recruiting|
|Hamilton, Ontario, Canada, L8N 4A6|
|Contact: Peter R. A. Malik, BHSc 905-522-1155 ext 35096 firstname.lastname@example.org|
|Contact: Yogita S Patel, BSc 905-522-1155 ext 35096 email@example.com|
|Principal Investigator: Wael C. Hanna, MDCM, MBA, FRCSC|
|Principal Investigator:||Waël C Hanna, MDCM, MBA, FRCSC||St. Joseph's Healthcare Hamilton / McMaster University|